key: cord-0861859-2w52cl91 authors: Long, Zhen; Wei, Chen; Xuefang, Dong; Li, Xiuling; Yang, Hao; Deng, Haiqing; Ma, Xiao; Yin, Shanshan; Qi, Yingzi; Bo, Tao title: Simultaneous quantification of spike and nucleocapsid protein in inactivate COVID-19 vaccine bulk by liquid chromatography-tandem mass spectrometry date: 2021-08-05 journal: J Chromatogr B Analyt Technol Biomed Life Sci DOI: 10.1016/j.jchromb.2021.122884 sha: 12491af4bed12ea6d5cc592df20cdd6e6b0d4e28 doc_id: 861859 cord_uid: 2w52cl91 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines are the most promising approach to control the COVID-19 pandemic. There are eminent needs to develop robust analytical methods to ensure quality control, as well as to evaluate the long-term efficacy and safety of vaccine. Although in vivo animal tests, such as serum-based ELISA, have been commonly used for quality control of vaccines, these methods have poor precision, are labor intensive, and require the availability of expensive, specific antibodies. Thus, there is growing interest to develop robust bioanalytical assays as alternatives for qualitative and quantitative evaluation of complex vaccine antigens. In this study, a liquid chromatography tandem mass spectrometry method was developed using optimized unique peptides for simultaneous determination of spike (S) and nucleocapsid (N) protein. Method sensitivity, linearity, repeatability, selectivity, and recovery were evaluated. The amount of S and N proteins in 9 batches of inactivated COVID-19 vaccines were quantified, and their compositions relative to total protein content were consistent. We believe this method can be applied for quality evaluation of other S and/or N protein based COVID-19 vaccine, and could be extended to other viral vector, and protein subunit-based vaccines. The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has triggered a global public health crisis [1] . Vaccines are expected to be the most promising solution to control SARS-CoV-2, which lead to accelerated development of effective vaccines against SARS-CoV-2 [2, 3] vaccines. Enable to support this increasing demand, rapid and robust bioanalytical assays are needed to ensure the quality, efficacy, and safety of the vaccines. In SARS-CoV-2, there are more than ten kinds of antigens reported [6] . Among them, spike (S) protein is the main antigen. Moreover, nucleocapsid (N) protein, a multifunctional protein which forms complexes with genomic RNA and plays a critical role in virus transcription and assembly, is the most abundant protein in SARS-CoV-2, poorly and non-neutralizing antibodies produced as result of immunogenic response to these proteins in inactivated COVID-19 vaccine could exacerbate subsequent infections via antibody-dependent enhancements (ADE) mechanism, which was also reported previously as a possible cause for enhanced infections of SARS-CoV and middle east respiratory syndrome coronavirus (MERS-CoV) [7] [8] [9] . Thus, quantifying the composition of S and N proteins are useful for determining the efficacy and safety of inactivated COVID-19 vaccine. Traditionally, in vivo animal tests such as serum ELISA (enzyme linked immunosorbent assay) assays, have been used to measure produced antibodies as a result of immunization response to administered vaccines. However, these assays have many practical challenges, including inherent variability in their accuracy and precision as well as being technically challenging, labor intensive and time consuming to routinely run in an analytical laboratory [10, 11] . For example, vaccine matrix such as adjuvant usually leaded to unstable results of ELSA methods. Thus, a complex desorption pretreatment was needed for vaccine before it was detected by ELISA method. More importantly, highly specific S and N antigens are needed as cross reactivity between similar analogues of S and N proteins could generate false positive responses. Thus, a more selective and robust bioanalytical method is needed to better characterize and quantify these vaccine antigens. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) offers exciting and important opportunities to better characterize complex vaccine antigens due to its superior sensitivity and selectivity [12, 13] . Multi-reaction monitor (MRM) based LC-MS/MS methods had been established previously for the determination of antigens in pneumococcal polysaccharide [14] , diphtheria tetanus acellular pertussis (DTaP) vaccine [15] , glycoconjugate vaccines [16] and nine-valent human papilloma virus vaccines [17] . Compared to MRM-based method, parallel reaction monitoring (PRM) based method provides a more precise characterization result as it allows parallel detection of all target product ions in a single analysis using a high resolution and accurate mass analyzer. In addition, PRM requires less method development and is potentially more specific than MRM; therefore, it is widely adopted for quantitative analysis of complex metrics, such as proteomics as well as translational studies [18, 19] . Herein, we describe the development and application of a LC-PRM method for bioanalysis of S and N protein in 9 batches of inactivated COVID-19 vaccine bulk. We believe this method would be an attractive alternative to conventional serum-based ELISA for quality control of inactivated and other protein-based COVID-19 vaccines. Reference proteins (S and N protein) were obtained from National Institutes for Table 1 . For all sample runs, a diverter valve was used to stream the effluent to waste for the first 2 minutes before switching back to MS for the remainder of runs. Data acquisition was performed with Xcalibur™ 4.4 software and data analysis and relative quantification was performed with Proteome Discoverer™ 2.5 software. For all LCMS runs, positive HESI was used with spray voltage set at 3.8 kV. Both sheath gas and aux gas flow were set at 35 and 10, respectively. Ion transfer capillary temperature was set at 250 o C and aux gas heater temperature was set at 350 o C. For the quantitative analysis of N and S proteins, PRM was used with mass resolution set at 17500 and isolation window set at 1.6 m/z. Peaks were fragmented using HCD with NCE set at 22%. Spectrum data type was profile. Total protein content was determined by using the Lowry protein assay which was previously described in Chinese Pharmacopeia method [20] . Bovine serum albumin (BSA) was used as the standard, and inactivated COVID-19 vaccine was determined at 650 nm. Measured concentrations were corrected to account for dilutions. Reliable quantification of S and N proteins requires selection of unique signature peptides that are specific to the proteolytic proteins and are free of endogenous interferences from the inactivated COVID-19 vaccines. Hence, both tryptic and chymotryptic digestion methods were explored. With chymotryptic digestion, only 5 peptides from S protein and 3 peptides from N protein yielded adequate MS response (i.e., signal intensities higher than 1e 8 ). With tryptic digestion, not only it yields more peptides (e.g., 39 and 33 peptides for S and N protein respectively), signal intensities of the resultant peptides were higher as well. Therefore, trypsin was chosen to digest inactivated COVID-19 vaccine bulk for the remaining studies. Given the complex formulation of the inactivated COVID-19 vaccine, the ability to identify all proteins and quantify their relative abundance are important for vaccine characterization as well as quality control during production scaling and pre-and clinical studies. With tryptic digestion, 39 proteins (shown in Supporting Information 1) were identified from inactivated COVID-19 vaccine bulk including N protein, S protein, M protein and some host cell proteins (HCP). However, E protein, an important structural protein, was not detected which may have been filtered during the sample purification step. As for S proteins, 39 unique peptides were identified whereas 33 unique peptides were identified in N proteins. Among these unique peptides, 23/39 and 18/33 peptides suffer poor sensitivity as well as presence of post-translational modifications and unstable amino acid (such as methionine or cysteine) in their sequences. Five copies of S and N protein with the same amount was digested. The relative standard deviation (RSD%) of target peptide peak area obtained these samples was used to evaluate the repeatability of target peptides. Peptides with RSD% values of peak area less than 20% were used to evaluate peptide linearity. Five copies of S and N protein mixture with five different concentration was digested and the digestion was analyzed to evaluate linearity of target peptides. As a result, only 6 peptides of S protein and 4 peptides of N protein had good linearity and repeatability. Among those, the 2 most sensitive peptides, from different regions (i.e., one located at the receptor binding domain or RBD, and the other located at non-RBD portion of the protein), were selected for quantitative analysis of S and N proteins. Table 2 listed the peptide sequences and PRM transitions for S and N proteins, and sample tandem mass spectra of peptides were shown in Figure 1 . The ability to simultaneously detect and quantify both peptides for each protein will provide confidence in the determined amount and serve a good indicator for batch-to-batch reproducibility and digestion efficiency. Linearity, sensitivity, selectivity, precision, and recovery were evaluated using the optimized PRM method for quantitation of S and N protein in inactivated COVID-19 vaccine bulk. The linearity of the quantification method was measured by selecting 9 different concentrations tested across the range 1-25 µg/mL for S protein and 10-80 µg/mL for N protein. The linear regression fit was applied with 1/C weight. As shown in Table 3 , the method demonstrated good linearity across tested concentration 1-25 µg/ml and 10-80 µg/ml with the regression correlation coefficient R 2 ≥ 0.993 for signature peptides of S and N protein, respectively. The PRM method exhibits excellent accuracy, all within the range of 91.4-110.1% across check standards. The lower limit of quantitation (LLOQ), which was defined as the lowest concentration level measured with 20% precision and 80%-120% accuracy, was determined to be 0.1 µg/ml for S and N protein (Table 3) . Sample extracted ion chromatograms (XIC) of quantifier ions at LLOQ level (top) and in blank (bottom) for S and N protein were shown in Figure 2 . This method demonstrates high selectivity towards S and N proteins as no endogenous interferences were observed in blank samples which contained all components in vaccine, except inactivated SARS-Cov-2. Intra-day precision (n=5) was evaluated by analysis of QC samples on the same day. The concentrations of S and N protein in QC samples were 5 and 20 µg/mL, respectively. Inter-day precision was determined by repeated analyses of the QC samples in five consecutive days. As shown in Table 3 , the method exhibits excellent reproducibility as both intra-day and inter-day precision are well within 8% for quantified S and N proteins. The optimized PRM method was applied to quantify S and N proteins in nine batches of inactivated COVID-19 vaccines. The results were shown in Table 4 . According to the results in Table 4 , the concentrations of S and N protein in inactivated COVID 19 vaccine bulk are higher than 4 and 15 µg/mL, respectively. This means that the sensitivity of the current LC-MS/MS method is adequate for targeted quantitation of S and N protein in inactivated COVID 19 vaccine bulk. Table 4 , although the determined amount of S and N proteins in each batch vary slightly, the composition (i.e., % S and N protein relative to the total protein concentration) are rather consistent, with a relative standard deviation around 20% across 9 batches. The possible reason that could account for such variation is that the inactivated SARS-CoV-2 virus (bulk) was damaged during purification process leading to loss of some proteins, such as E protein. This was verified via electron microscopy imaging of the vaccines (Fig. 3) , showing the damaged inactivated SARS-CoV-2 species. The protein composition study in Section 3.2 also verified that no E protein was detected in inactivated COVID-19 vaccine bulk. The total amount of S and N proteins contributed to about 48.5%-89.6% of the total proteins in inactivated COVID-19 vaccine bulk, and other proteins accounted for about 10.4%-51.5% in inactivated COVID-19 vaccine bulk, consistent with other reporting [6] . Despite many reported articles on SARS-CoV-2 viral proteins, the roles of these other proteins remain unclear. We believe current LC-MS/MS method could be extended to quantify these proteins when researchers gain better understanding on these viral proteins and how they could impact the safety and efficacy of the vaccines. S protein amount in the studied samples was also measured by an ELISA method developed by the manufacture (Fig.4) . The RSD value of this ELISA method was in the range of 6%-8%. Details of this method was shown in Supporting Information 2. As shown in Fig. 4 In this study, a PRM based LC-MS/MS method was developed and applied for quantitative determination of S and N protein in inactivated COVID-19 vaccine bulk. The quantitative method was optimized and then used to determine the amount of S and N proteins simultaneously in inactivated COVID-19 vaccine bulk. The batch-to-batch stability of inactivated COVID-19 vaccine was studied in terms of the RSD% of S and N proteins. The LC-MS/MS method consistent the results obtained with ELISA method for most samples, while LC-MS/MS method is more robust due to its high selectivity. Besides inactivated COVID-19 vaccine, this method can also be used to determine S and/or N protein, as well as HCPs in other protein based COVID-19 vaccines. Development of an inactivated vaccine candidate for SARS-CoV-2 Contingent assessment of the COVID-19 vaccine Vaccines for COVID-19: The current state of play The Architecture of SARS-CoV Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization Vaccines for the prevention against the threat of MERS-CoV Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins Pertussis Serological Potency Test as an Alternative to the Intracerebral Mouse Protection Test: Development, Evaluation and Validation The Pertussis Serological Potency Test Collaborative Study to Evaluate Replacement of the Mouse Protection Test Glycosylation of viral surface proteins probed by mass spectrometry Global and site-specific analysis of protein glycosylation in complex biological systems with Mass Spectrometry A fast and robust hydrophilic interaction liquid chromatography tandem mass spectrometry method for determining methylpentose, hexose, hexosamine and hexonic acid in pneumococcal polysaccharide vaccine hydrolysates Quantitative determination of bioactive proteins in diphtheria tetanus acellular pertussis (DTaP) vaccine by liquid chromatography tandem mass spectrometry Determination of glycosylation degree for glycoconjugate vaccines using a solid-phase extraction combined with liquid chromatography and tandem mass spectrometry method Simultaneous determination of capsid proteins in nine-valent human papilloma virus vaccines by liquid chromatography tandem mass spectrometry Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer Pharmacopoeia of the People's Republic of China protein was simultaneously determined by the developed method. 2. The developed method was accurate and sensitive, and it was faster than vivo animal tests It can be used to evaluate other protein-based COVID-19 vaccines The authors thank the financial support by National Natural Science Foundation of China (21974135 and 21775148).The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.